Investors & Media

Press Releases

Date Title and Summary Additional Formats
Toggle Summary ImmunoGen, Inc. Announces Conference Call to Discuss its Fourth Quarter and Fiscal Year 2015 Financial Results
WALTHAM, Mass. --(BUSINESS WIRE)-- ImmunoGen, Inc . (Nasdaq: IMGN), a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today announced that the Company will host a conference call at 8:00 a.m.
View HTML
Toggle Summary ImmunoGen, Inc. Reports Fourth Quarter and Fiscal Year 2015 Financial Results
− Company Provides Corporate Update and Fiscal Year 2016 Financial Guidance − − Conference Call Today at 8:00 am ET − ImmunoGen's wholly owned mirvetuximab soravtansine demonstrates notable single-agent activity in early clinical testing for platinum-resistant ovarian cancer; Company plans to
View HTML
Toggle Summary ImmunoGen, Inc. Announces Canaccord Genuity Growth Conference Webcast
WALTHAM, Mass. --(BUSINESS WIRE)-- ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today announced the Company will participate in the Canaccord Genuity 35 th Annual Growth Conference.
View HTML
Toggle Summary ImmunoGen, Inc. Announces Webcast of its Analyst and Investor Event on September 18, 2015
WALTHAM, Mass. --(BUSINESS WIRE)-- ImmunoGen, Inc . (Nasdaq: IMGN), a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today announced that investors, journalists and the general public are invited to listen to a live webcast of
View HTML
Toggle Summary ImmunoGen, Inc. Announces Morgan Stanley Global Healthcare Conference Webcast
WALTHAM, Mass. --(BUSINESS WIRE)-- ImmunoGen, Inc . (Nasdaq: IMGN), a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today announced the Company will participate in the Morgan Stanley Global Healthcare Conference .
View HTML
Toggle Summary Webcast of the ImmunoGen, Inc. Analyst & Investor Event on September 18, 2015
WALTHAM, Mass. --(BUSINESS WIRE)-- ImmunoGen, Inc . (Nasdaq: IMGN), a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today announced that investors, journalists and the general public are invited to listen to a live webcast of
View HTML
Toggle Summary ImmunoGen, Inc. Announces Conference Call to Discuss its First Quarter Fiscal Year 2016 Financial Results
WALTHAM, Mass. --(BUSINESS WIRE)-- ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today announced that the Company will host a conference call at 8:00 a.m.
View HTML
Toggle Summary ImmunoGen Reports First Quarter Fiscal Year 2016 Financial Results and Provides Corporate Update
− Conference Call Today at 8:00 am ET − Level of target expression on patient tumors may have a marked impact on response to mirvetuximab soravtansine, ImmunoGen's novel folate receptor α (FRα)-targeting antibody-drug conjugate (ADC); data to be reported at AACR-NCI-EORTC in November.
View HTML
Toggle Summary Treatment Response to ImmunoGen's Mirvetuximab Soravtansine Found to be Substantially Greater in Ovarian Cancer with High Expression of Folate Receptor Alpha
Objective response on mirvetuximab soravtansine in nine of ten (90%) patients with high amounts of target on cancer cells; majority of these responders remained on treatment for at least 24 weeks Most patients with ovarian cancer found to have high or medium expression of target FORWARD I ovarian
View HTML
Toggle Summary ImmunoGen Named One of The Boston Globe's Top Places to Work for Third Consecutive Year
WALTHAM, Mass. --(BUSINESS WIRE)-- ImmunoGen, Inc . (Nasdaq: IMGN), a biotechnology company that develops targeted anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today announced that it has been named one of The Boston Globe's Top Places to Work.
View HTML